Introduction to Targeted Therapies in OncologyMohamed Abdulla
Describes the molecular background which represents the core for developing targeted therapies against specific biological events in malignant cellular clones.
Introduction to Targeted Therapies in OncologyMohamed Abdulla
Describes the molecular background which represents the core for developing targeted therapies against specific biological events in malignant cellular clones.
Recent advancements in metastatic colorectal cancer treatmentKindai University
In this presentation, the presenter tries to provide an overview of the current established treatment strategies, based on their clinical outcomes as well as their mechanisms, limitations that remain to be overcome, and their future applicability for the treatment of human Colorectal Cancer.
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Liquid Biopsy in Oncology : Non-Invasive Diagnosis for Cancer PatientsKumaraguru Veerasamy
In this SlideShare, we explore the potentially game-changing diagnostic and monitoring method for cancer patients, known as Liquid Biopsy. A simple and non-invasive alternative to conventional surgical biopsies , liquid biopsy enables doctors to discover a range of information about a patient's tumor through a simple blood sample . We will also cover on how Intervenn's unique glycoproteomics & AI analysis platform is being developed to detect colorectal pre-cancer.
Pruebas genómicas de recurrencia en cáncer de mama - OncotypeDx y su entornoMauricio Lema
Presentación para el simposio satélite de Amarey en el marco del congreso de los 85 años del Instituto Nacional de Cancerología, Hotel Hyatt, 29.08.2019, Bogotá
Don't miss our upcoming webinars! Subscribe today!
Presented by: Dr. Poul Sorensen, MD, PhD, FRCPC; Dr. Muhammad Zulfiqar, MD; Ted Taylor, Patient Advocate
In this webinar, we will hear from Dr. Sorensen about his groundbreaking discovery and how it contributed to the development of tumour agnostic treatments. Dr. Zulfiqar, a medical oncologist at the BC Cancer Agency, will further discuss TRK fusion cancers and how he has been able to treat patients. Lastly, we will hear from Ted Taylor, a TRK fusion cancer patient diagnosed with glioblastoma (GBM) multiform being treated with Vitrakvi.
Watch the YouTube video: https://youtu.be/RAkItUeZ23Q
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
Recent advancements in metastatic colorectal cancer treatmentKindai University
In this presentation, the presenter tries to provide an overview of the current established treatment strategies, based on their clinical outcomes as well as their mechanisms, limitations that remain to be overcome, and their future applicability for the treatment of human Colorectal Cancer.
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Liquid Biopsy in Oncology : Non-Invasive Diagnosis for Cancer PatientsKumaraguru Veerasamy
In this SlideShare, we explore the potentially game-changing diagnostic and monitoring method for cancer patients, known as Liquid Biopsy. A simple and non-invasive alternative to conventional surgical biopsies , liquid biopsy enables doctors to discover a range of information about a patient's tumor through a simple blood sample . We will also cover on how Intervenn's unique glycoproteomics & AI analysis platform is being developed to detect colorectal pre-cancer.
Pruebas genómicas de recurrencia en cáncer de mama - OncotypeDx y su entornoMauricio Lema
Presentación para el simposio satélite de Amarey en el marco del congreso de los 85 años del Instituto Nacional de Cancerología, Hotel Hyatt, 29.08.2019, Bogotá
Don't miss our upcoming webinars! Subscribe today!
Presented by: Dr. Poul Sorensen, MD, PhD, FRCPC; Dr. Muhammad Zulfiqar, MD; Ted Taylor, Patient Advocate
In this webinar, we will hear from Dr. Sorensen about his groundbreaking discovery and how it contributed to the development of tumour agnostic treatments. Dr. Zulfiqar, a medical oncologist at the BC Cancer Agency, will further discuss TRK fusion cancers and how he has been able to treat patients. Lastly, we will hear from Ted Taylor, a TRK fusion cancer patient diagnosed with glioblastoma (GBM) multiform being treated with Vitrakvi.
Watch the YouTube video: https://youtu.be/RAkItUeZ23Q
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
13. がん化学療法の目的
• 固形がんの補助化学療法
• 化学療法高感受性がんの初回化学療法
• 進行がんの化学療法
• 再発がんの化学療法
15/02/26
Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital
→できるだけDose intensity (治療強度）を保つため、む
やみに、減量・延期をしない
→患者さんのQOL（生活の質）を保つため、毒性に応じ
て投与規準変更を行う
14. 抗がん剤投与量（減量）と生命予後
0
5
10
15
20
20
40
60
80
100
0
乳がん患者における術後補助療法（CMF療法）の抗がん剤投与量と生命予後との関連
推奨用量に対する割合
Control
＜65%
65–84%
≧85%
全
生
存
率
（
％
）
乳房切除後の期間 （年）
0
5
10
15
20
20
40
60
80
100
0
無
再
発
生
存
率
（
％
）
(n=179)
(n=71)
(n=94)
(n=42)
乳房切除後の期間 （年）
Bonadonna
G
et
al.
N
Engl
J
Med,
332
:
901-‐906,
1995
Division of Medical Oncology, Nippon Medical School Musashikosugi Hospital
15. Average dose intensity (DI) v MST
for ovarian chemotherapy regimens.
JCO
5:756-767,
1987
10
20
30
40
0
0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
P
PP
C
C
CC
C
C
C
C
C
C
CC
C
C
C
C
C
●
●
●
●
●
●
●
●
▲
▲
▲
▲
▲
▲
▲
▲
□
□
□
□
□
□
□
■
■
◇
○
○
△
△
△
average
DI
MST
(mos.)
▲
CHAP
●
CAP
■
CHA
◇
CH
□
CA
○
CP
△
AP
r=0.44
(p
0.01)
25. Types of dose-dense chemotherapy
• Conventional treatment
• Dose-dense treatment
n Same doses, same agents
n Similar doses, different agents
n Reduced doses, same agents
J Natl Cancer Inst 2010;102:1845
26. Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer:
AMeta-analysis of Randomized Controlled Trials
J Natl Cancer Inst 2010;102:1845
Linden 2007 0.90 (0.76 to 1.07)
Untch 2009 0.66 (0.38 to 1.15)
Moebus2003 0.65 (0.44 to 0.96)
Therasse 2003 0.99 (0.76 to 1.29)
Von Minckwitz 2003 0.79 (0.54 to 1.17)
Kummel 2006 0.57 (0.30 to 1.10)
Subtotal 0.85 (0.75 to 0.96)
All trials combined (95% CI) 0.85 (0.77 to 0.93)
Baldini 2003 0.87 (0.49 to 1.55)
Citron2003 0.81 (0.66 to 1.00)
Venturini 2005 0.88 (0.68 to 1.15)
Subtotal 0.84 (0.72 to 0.98)
Trials with same doses, same agents
Favors
dose-dense
chemotherapy
Favors
conventional
chemotherapy
0.2 0.5 1.0 2.0 5.0
Trials with similar doses, different agents
32. 分子標的薬剤の分類
標的分子
薬剤（一般名）
（商品名） 適応
HER
HER
HER
HER
EGFR
EGFR
EGFR
EGFR
VEGF
Multi target
Multi target
Multi target
Multi target
Multi target
m-TOR
m-TOR
ALK
ALK
PDL1
トラスツズマブ
ラパチニブ
ペルツズマブ
TDM-1
エルロチニブ
アファチニブ
セツキスマブ
パニツズマブ
ベバスズマブ
ソラフェニブ
スニチニブ
アキシチニブ
パゾパニブ
レゴラフェニブ
テムシロリムス
エベロリムス
クリゾチニブ
アレクチニブ
ニボルマブ
ハーセプチン
タイケルブ
パージェタ
カドサイラ
タルセバ
ジオトリフ
アービタックス
ベクティビックス
アバスチン
ネクサバール
スーテント
インライタ
ヴォトリエント
スチバーガ
トリセル
アフィニトール
ザーコリ
アレセンサ
オプチーボ
乳がん、胃がん
乳がん
乳がん
乳がん
肺がん、膵がん
肺がん
大腸がん、頭頸部がん
大腸がん
大腸がん、肺がん、乳がん
腎がん、肝がん、甲状腺がん
腎がん、GIST
腎がん
軟部肉腫、腎がん
大腸がん、GIST
腎がん
腎がん、膵内分泌がん
肺がん
肺がん
悪性黒色腫
33. immune-checkpoint inhibitor
抗PD-1（programmed cell death-1）抗体の作用機序
15/02/26
Division of Medical Oncology, Nippon Medical School Musashikosugi Hospital
Arch Dermatol Res (2014) 306:511–519
Nivolumab：2014悪性黒色腫に承認、非小細胞肺がん、腎臓がんなどで治験中
